Skip to main content
Log in

Medication-induced hallucination and cerebral blood flow in Parkinson’s disease

  • Original communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Although hallucinations in Parkinson’s disease (PD) are not unusual in the long-term treatment with anti-parkinsonian agents, their mechanism is not fully understood. We compared both the neuropsychiatric state and the results of 99mTc-labeled hexamethyl propyleneamine oxime single-photon emission computed tomography in 12 PD patients with medication-induced hallucinations and 21 PD patients without hallucinations. Hallucinatory patients showed significantly lower cerebral blood flow in left temporal regions than nonhallucinatory patients. The cerebral blood flow reduction in these regions may be related to the mechanism of medication-induced hallucinations in PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 19 May 1998 Received in revised form: 15 September 1998 Accepted: 26 September 1998

Rights and permissions

Reprints and permissions

About this article

Cite this article

Okada, K., Suyama, N., Oguro, H. et al. Medication-induced hallucination and cerebral blood flow in Parkinson’s disease. J Neurol 246, 365–368 (1999). https://doi.org/10.1007/s004150050364

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s004150050364

Navigation